Czechowska Kamila, Bonilla Diana L, Cotty Adam, Dankar Amay, Mead Paul E, Nash Veronica
Metafora Biosystems, 75014 Paris, France.
Cytek Biosciences Inc., Fremont, CA 94538, USA.
Cells. 2025 Jun 30;14(13):997. doi: 10.3390/cells14130997.
Spectral flow cytometry has revolutionized traditional single-cell profiling to a new era of high-dimensional analysis, allowing for unprecedented deep phenotyping and more precise cell characterization, thereby significantly enhancing our multiplexing capability. The recent application of this technology in clinical settings has been redefining the landscape of clinical diagnostic panels and immune monitoring, particularly for hematologic malignancies, immunological disorders, and drug discovery. Emerging technologies like ghost cytometry, LASE, and imaging flow cytometry are advancing cytometry by improving sensitivity, throughput, and spatial resolution. In this review, we discuss the requirements, challenges, and considerations for spectral applications in clinical diagnostic laboratories and pharmaceutical/contract research organization (CRO) settings. We discuss how these recent innovations are set to push the boundaries of diagnostic accuracy and analytical power, heralding a new frontier in clinical cytometry with the potential to dramatically enhance patient care and treatment outcomes.
光谱流式细胞术已将传统的单细胞分析带入了一个高维分析的新时代，实现了前所未有的深度表型分析和更精确的细胞表征，从而显著提高了我们的多重分析能力。该技术最近在临床环境中的应用正在重新定义临床诊断面板和免疫监测的格局，特别是对于血液系统恶性肿瘤、免疫紊乱和药物研发。诸如幻影流式细胞术、激光激活细胞分选技术（LASE）和成像流式细胞术等新兴技术，正通过提高灵敏度、通量和空间分辨率推动流式细胞术的发展。在这篇综述中，我们讨论了光谱技术在临床诊断实验室以及制药/合同研究组织（CRO）环境中应用的要求、挑战和注意事项。我们探讨了这些最新创新如何推动诊断准确性和分析能力的边界，开创临床流式细胞术的新前沿，有可能显著改善患者护理和治疗效果。
